- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer ; volume:10 ; number:1 ; day:13 ; month:4 ; year:2010 ; pages:1-9 ; date:12.2010
BMC cancer ; 10, Heft 1 (13.4.2010), 1-9, 12.2010
- Creator
-
Sánchez-Muñoz, Alfonso
- Contributor
-
Gallego, Elena
de Luque, Vanessa
Pérez-Rivas, Luís G.
Vicioso, Luís
Ribelles, Nuria
Lozano, José
Alba, Emilio
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-10-136
- URN
-
urn:nbn:de:1111-2016030354665
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sánchez-Muñoz, Alfonso
- Gallego, Elena
- de Luque, Vanessa
- Pérez-Rivas, Luís G.
- Vicioso, Luís
- Ribelles, Nuria
- Lozano, José
- Alba, Emilio
- SpringerLink (Online service)
Other Objects (12)
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes
Metastatic Triple-Negative Breast Cancer
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS promotes malignant brain tumors in zebrafish
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Oncogenic potential of rare RRAS2 mutations
The pseudokinase NRBP1 activates Rac1/Cdc42 via P-Rex1 to drive oncogenic signalling in triple-negative breast cancer
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes
Metastatic Triple-Negative Breast Cancer
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS promotes malignant brain tumors in zebrafish
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Oncogenic potential of rare RRAS2 mutations
The pseudokinase NRBP1 activates Rac1/Cdc42 via P-Rex1 to drive oncogenic signalling in triple-negative breast cancer
CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502–5p/KRAS and IGF2BP2/Myc axes
Metastatic Triple-Negative Breast Cancer
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KRAS promotes malignant brain tumors in zebrafish
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Oncogenic potential of rare RRAS2 mutations